prIME 3.0 New Activity Landing Page Layout - priME Oncology
Patient Education
Patient Education

prIME 3.0 New Activity Landing Page Layout

H2 lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna H2.

View Activity

Not a member of My prIME? Join now for instant access.

Restricted Activity Message H2 lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna H2. Overview Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim

Release Date

Release Date

Feb 23, 2018

Expiration Date

Feb 23, 2019

IME

IME

Downloadable Slides

Downloadable Slides

CE

CE

eNewsletter

eNewsletter

Location

Location

Global

Date/Time

Date/Time

Animation

Animation

Interactive Presentation

Interactive Presentation

Patient Education

Patient Education

Newsflash

Newsflash

Simulcast

Simulcast

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Custom Block Displays Anywhere?

prIME Custom Block:
5 min Hematology Guru: How well do you know marginal zone lymphoma?
15 min Marginal zone lymphoma 101: Diagnosis and tumor biology
5 min Questions from the audience
20 min 2017 and beyond: What does the future hold for marginal
zone lymphoma?
5 min Questions from the audience
5 min Hematology Guru: How well do you know marginal zone lymphoma?
5 min Conclusions and prIME Points™

prIME Faculty Members

  • Elisabetta Abruzzese, MDSan Eugenio Hospital
    Rome, Italy
  • Francesco Zaja, MDUniversity of Udine
    Udine, Italy
  • Neil Vasan, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Genolier, Switzerland
  • Shaad Essa Abdullah, MDGreater Washington Oncology Associates
    Bethesda, Maryland
  • Ghassan Abou-Alfa, MD, MBAMemorial Sloan Kettering Cancer Center
    New York, New York, United States

2nd prIME Faculty Members 2

  • Athanassios Argiris, MD, PhD, FACPHygeia Hospital
    Athens, Greece
  • Aristotle Bamias, MD, PhDNational and Kapodistrian University of Athens
    Athens, Greece
  • Charles Bane

Topics

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2 end.

Target Audience

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Learning Objectives

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Support

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.H2lorem ipsum dolor sit amet, consectetur adipiscing elit, seddo eiusmod tempor incididunt ut labore et dolore magna H2.do eiusmod tempor incididunt ut labore et dolore magna H2.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

Provider H2 lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna H2. Overview Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr x has disclosed that he has received consulting fees from company. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

  • Bojana Pajk, MD, MSc (medical content reviewer/planner) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.